… EGFR tyrosine kinase inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive
non-small-cell lung cancer. In … - and third-generation EGFR TKIs in Asian populations, …

… data of EGFR-TKIs in EGFR-positive NSCLC patients (EGFR … answer which EGFR-TKI is
the best clinical choice for EGFR-… the optimized selection of EGFR-TKIs is different between …

… [4] It remains controversial whether PD-L1 TPS is predictive for EGFR TKI efficacy as … line
1st/2nd EGFR TKI in a metropolitan population with EGFR-mutant lung adenocarcinoma. It also …

… (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced
non-small cell lung cancer (… an EGFR WT genotype who were treated with an EGFR-TKI for …

… the EGFR TKI until tumor become resistant beyond chemotherapy, stop chemotherapy and
switch to EGFR TKI, introduce the EGFR TKI as … or concurrent EGFR TKI plus chemotherapy. …

… (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with different mechanisms
of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is … mutation of EGFR. …

… receptor (EGFR) gene mutations [3]. Currently, various EGFR tyrosine kinase inhibitors (EGFR-TKIs)
are standard treatment options for patients with activating EGFR gene mutations. …

… to EGFR TKIs, the vast majority of EGFR-mutated lung cancer cells are killed within a few days
upon exposure to a clinically relevant concentration of an EGFR TKI, … of an EGFR TKI [21]. …

… growth factor receptor (EGFR) T790 M mutation-positive non-small cell lung cancer (NSCLC),
as detected by an US FDA-approved test, whose disease has progressed on or after …

… and many other types of cancer. Currently, two reversible EGFR tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, and one irreversible EGFR, human epidermal growth …